Published: Tue, November 14, 2017
Business | By Max Garcia

Trader Alert: Unusual Volume Spotted in Nektar Therapeutics (NASDAQ:NKTR)

Trader Alert: Unusual Volume Spotted in Nektar Therapeutics (NASDAQ:NKTR)

Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company's stock valued at $1,582,000 after buying an additional 800 shares in the last quarter. Prelude Capital Management Ltd Limited Liability Company reported 0.08% stake.

Several institutional investors have recently made changes to their positions in NKTR. Panagora Asset Mgmt has invested 0.07% in Nektar Therapeutics (NASDAQ:NKTR). The company's price to sales ratio for trailing twelve months is 13.51 and price to book ratio for most recent quarter is 2.27, whereas price to cash per share for the most recent quarter is 62.20.

For the Current Quarter, the growth estimate for Nektar Therapeutics is -14.3%, while for the Next Quarter the stock growth estimate is 16.7%. Bank of Montreal Can now owns 6,395 shares of the biopharmaceutical company's stock valued at $110,000 after buying an additional 208 shares during the last quarter. Da Davidson And holds 0% in Nektar Therapeutics (NASDAQ:NKTR) or 4,600 shares. Insiders have sold a total of 1,024,757 shares of company stock valued at $25,974,361 in the last ninety days. HighTower Advisors LLC raised its holdings in shares of Nektar Therapeutics by 10.4% during the first quarter. US Bancorp DE now owns 94,005 shares of the biopharmaceutical company's stock valued at $1,615,000 after buying an additional 665 shares during the last quarter. Nicholson John sold $1.96 million worth of Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, June 7. (NYSE:VG) earned "Buy" rating by Dougherty & Company on Friday, August 4.

Nektar Therapeutics (NASDAQ:NKTR) was the recipient of some unusual options trading activity on Thursday.

Investors saw a positive move of 36.84% in last five trading days. The company has market cap of $2.05 billion. Currently, the stock is -65.53% from its 50-Day High and 224.00% from the 50-day low. The value of the investment in NKTR increased from $402,000 to $491,000 increasing 22.1% quarter to quarter. After $0.21 actual earnings per share reported by Cypress Semiconductor Corporation for the previous quarter, Wall Street now forecasts -14.29% negative EPS growth. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The firm had revenue of $152.90 million for the quarter, compared to the consensus estimate of $126.50 million. Over the past month the firm's stock is 41.18%, 68.57% for the last quarter, 64.06% for the past six-months and 137.57% for the a year ago. The business's revenue was down 39.4% on a year-over-year basis.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. "Has $6,567,000 Stake in Nektar Therapeutics (NKTR)" was posted by and is owned by of. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and worldwide trademark & copyright law. Financial Architects Incorporated stated it has 0% in Nektar Therapeutics (NASDAQ:NKTR). Jefferies Group LLC reaffirmed a "buy" rating and issued a $35.00 price target on shares of Nektar Therapeutics in a report on Wednesday, November 8th.

The consensus recommendation, according to Zacks Investment research, is 1.25. Canaccord Genuity assumed coverage on Nektar Therapeutics in a research report on Thursday. The stock presently has a consensus rating of "Buy" and an average target price of $31.82. August 18 investment analysts at Jefferies Group LLC left the company rating at "Buy" projecting a price of $23.00.

In other news, CEO Howard W. Robin sold 91,714 shares of the company's stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $29.00, for a total transaction of $11,493,367.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director R Scott Greer acquired 15,000 shares of the firm's stock in a transaction dated Monday, October 24th. Following the acquisition, the director now directly owns 121,333 shares of the company's stock, valued at $1,637,995.50. The disclosure for this sale can be found here.

Nektar Therapeutics is a biopharmaceutical firm that discovers and develops medicines in areas of high unmet medical need.

Like this: